Quick Test to Fight C Diff
Along with MRSA, Clostridium difficile is proving to be a major
problem for hospitals worldwide. Triggered by antibiotic use, Clostridium
difficile is the main cause of hospital-acquired diarrhoea and, for the
elderly in particular, can be fatal. In the UK, for example, more than 50,000
inpatients aged over 65 have C. difficile infections. In addition,
community acquired infection seems to be rising with more than 15,000 cases a
year, three-quarters of whom had not been in hospital.1,2
Since culture, the gold standard for testing takes 2-3 days, Inverness Medical
has introduced two new rapid tests. TechLab® TOX A/B Quik Chek and
BioStar® OIA® CdTOX AB are specifically designed to
enable swift diagnosis and subsequent isolation of patients, reducing cross
contamination in clinical areas.
Delivering results in minutes,
both tests qualitatively detect C. difficile Toxins A & B directly
from human faecal specimens. Toxin A is an enterotoxin which appears to be
responsible for the clinical symptoms of diarrhoea and colonic inflammation,
while Toxin B, potentially the most potent cytotoxin known to man, is
responsible for the associated cell destruction. Clinical symptoms of C.
difficile associated disease (CDAD) were once thought to be solely due to
Toxin A. However, there is growing evidence that Toxin B may also play an
important role in the pathogenesis of C. difficile. According to
Inverness Medical’s VP International Business, David Walton, it is becoming
mandatory in an increasing number of countries to use a test that detects both
toxins: “We believe the BioStar OIA and TechLab rapid tests offer the physician
two valuable new options to obtain a rapid and accurate diagnosis and initiate
appropriate patient management.”